Design, Synthesis, Activity Evaluation and Molecular Docking Study of Novel Janus kinase Inhibitors

[1]  Adam R. Johnson,et al.  Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling. , 2019, Bioorganic & medicinal chemistry letters.

[2]  P. Sarzi-Puttini,et al.  Systemic rheumatic diseases: From biological agents to small molecules. , 2019, Autoimmunity reviews.

[3]  S. Castañeda,et al.  JAK-STAT inhibitors for the treatment of immunomediated diseases. , 2019, Medicina clinica.

[4]  Michael A. Galella,et al.  Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis. , 2019, ACS medicinal chemistry letters.

[5]  O. Silvennoinen,et al.  Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases , 2019, BioDrugs.

[6]  J. O’Shea,et al.  JAK inhibition as a therapeutic strategy for immune and inflammatory diseases , 2017, Nature Reviews Drug Discovery.

[7]  X. Roblin,et al.  Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects , 2017, Drugs.

[8]  K. Winthrop.  The emerging safety profile of JAK inhibitors in rheumatic disease , 2017, Nature Reviews Rheumatology.

[9]  D. Schwartz,et al.  JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects , 2017, Drugs.

[10]  P. Diderichsen,et al.  Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection , 2015, Clinical Pharmacokinetics.

[11]  L. Nelles,et al.  Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634. , 2014, Journal of medicinal chemistry.

[12]  Mark E Flanagan,et al.  Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. , 2014, Journal of medicinal chemistry.

[13]  Jennifer L. Mason,et al.  A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779. , 2012, Journal of medicinal chemistry.

[14]  R. Plenge,et al.  JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. , 2012, Immunity.

[15]  O. Perez,et al.  Fibrocyte activation in rheumatoid arthritis. , 2010, Rheumatology.

[16]  O. Smirnova,et al.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression? , 2007, World journal of gastroenterology.

[17]  S. Bhattacharya,et al.  Signaling through the JAK/STAT pathway, recent advances and future challenges. , 2002, Gene.

[18]  Peter Lipsky,et al.  Cytokines and autoimmunity , 2002, Nature Reviews Immunology.